An interventional study of TMS in Major Depression Disorder, sponsored by Gulhane Training and Research Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Gulhane Training and Research Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is the 17th largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 17th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:
Gulhane Training and Research Hospital · Sites in Turkey
Ages 18–55 · Healthy volunteers
Medipol University · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–60 · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 55+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 95 across the 24 interventional studies, 78 across the 8 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
Gulhane Training and Research Hospital is the lead sponsor of 44 studies on the registry; 8 are open to participants now.
Gulhane Training and Research Hospital has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
11 of the studies in Depressive Disorder, Major with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT07534475Medipol UniversityVenous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT | 2026-11-30 |
| NCT07748091Istanbul University - CerrahpasaEEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07740694Istanbul University - CerrahpasaEEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07603804Istanbul University - CerrahpasaAccelerated iTBS for Major Depression | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.
This prospective cohort study aims to investigate the relationship between plasma proteomic and metabolomic profiles and the treatment response to transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (TRD). TRD is defined as a subtype of major depressive disorder (MDD), characterized by an inadequate response to at least two adequate trials of antidepressant therapy. Despite the clinical efficacy of TMS as a non-invasive neuromodulation treatment, the biological underpinnings that determine patient responsiveness remain unclear. This study addresses that gap by evaluating blood-based molecular biomarkers that may predict or reflect TMS treatment outcomes.
A total of 55 TRD patients, diagnosed according to DSM-5-TR criteria and confirmed through the SCID-5 structured clinical interview, will be enrolled. An additional 55 healthy individuals matched for age and sex will serve as a control group for baseline plasma comparisons. Patients will undergo a standardized TMS protocol using the MagVenture™ X100™ device. The protocol includes 20 treatment sessions over four weeks, with each session delivering 1,800 pulses of intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC). Motor threshold will be assessed weekly to calibrate treatment intensity to 90% of the resting motor threshold.
Blood samples will be collected from TRD patients prior to the first TMS session and after the 20th session, while healthy controls will provide samples at a single time point. Proteomic analysis will be conducted using LC-MS/MS following protein extraction, digestion, and purification. Metabolomic profiling will be carried out using LC-MS coupled with ion mobility spectrometry, enabling the identification of a wide range of plasma metabolites.
Psychiatric assessments, including the Hamilton Depression Rating Scale (HAM-D), Patient Health Questionnaire-9 (PHQ-9), Pittsburgh Sleep Quality Index (PSQI), and the Clinical Global Impression (CGI) scale, will be administered at baseline and post-treatment to monitor clinical outcomes. Data integration and bioinformatics analyses will be performed using MaxQuant, Perseus, and MetaboAnalyst 6.0, enabling the identification of differentially expressed proteins and metabolites associated with treatment response.
The primary objective of the study is to determine whether plasma proteomic and metabolomic profiles differ significantly between TMS responders and non-responders. Secondary objectives include identifying predictive biomarkers for TMS efficacy and assessing biological changes correlated with clinical improvement.
Primary outcomes will focus on identifying molecular signatures that correlate with treatment responsiveness. Secondary outcomes will include changes in depression severity scores, documentation of any adverse effects related to TMS, and examination of correlations between biomarker expression and pharmacological history.
This study is crucial for advancing personalized treatment approaches in psychiatry. By identifying objective, blood-based biomarkers of TMS response, it may become possible to tailor treatment strategies, reduce unnecessary interventions, and improve therapeutic outcomes for individuals suffering from TRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes participants diagnosed with treatment-resistant depression (TRD) who will receive transcranial magnetic stimulation (TMS) therapy. TMS will be delivered using the MagVenture™ X100™ device. The treatment protocol consists of 20 sessions over a 4-week period (5 sessions per week). Stimulation will target the left dorsolateral prefrontal cortex (DLPFC) using intermittent theta burst stimulation (iTBS). Motor threshold will be determined at baseline and reassessed weekly to calibrate stimulation intensity at 90% of the resting motor threshold. Blood samples will be collected from participants at two time points: prior to the first TMS session (pre-treatment) and following the final (20th) session (post-treatment). Proteomic and metabolomic analyses will be performed using high-resolution liquid chromatography-mass spectrometry (LC-MS). The goal is to identify differentially expressed proteins and metabolites associated with clinical response to TMS.
Device: TMS
Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses. This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry.
Plasma Proteomic Profile Changes After TMS in Patients with Treatment-Resistant Depression
Assessment of differences in plasma proteomic profiles in treatment-resistant depression (TRD) patients before and after transcranial magnetic stimulation (TMS), using high-resolution liquid chromatography-mass spectrometry (LC-MS/MS) analysis. Changes in protein expression will be used to identify potential biomarkers of treatment response.
Time frame: From enrollment to end of treatment at 4 weeks
Plasma Metabolomic Profile Changes After TMS in Patients with Treatment-Resistant Depression
Evaluation of global metabolomic changes in plasma of TRD patients pre- and post-TMS therapy. Analysis will be conducted via liquid chromatography-mass spectrometry with ion mobility separation (LC-TIMS-TOF-MS), enabling identification of differential metabolites associated with clinical outcomes.
Time frame: From enrollment to end of treatment at 4 weeks
Fold Change in Baseline Proteomic Markers Between Treatment Responders and Non-Responders
Differences in baseline proteomic markers between treatment responders and non-responders will be assessed using LC-MS/MS. Fold change values will be calculated to identify proteins with significant differential expression between the two groups.
Time frame: From enrollment to end of the treatment at 4 weeks
Variable Importance in Projection Scores of Predictive Proteins
Variable Importance in Projection scores will be calculated using multivariate statistical analysis (e.g., PLS-DA) to rank the importance of baseline proteomic markers in distinguishing treatment responders from non-responders.
Time frame: Baseline and End of 4-week treatment
Area Under the ROC Curve for Predictive Proteomic Markers Between Treatment Responders and Non-Responders
Receiver Operating Characteristic (ROC) curve analysis will be performed to evaluate the predictive performance of baseline and end-of-treatment proteomic markers in distinguishing treatment responders from non-responders. Area Under the Curve (AUC) values will be calculated to assess discriminative ability.
Time frame: Baseline and End of 4-week treatment
Fold Change in Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders
Fold change in baseline plasma metabolomic expression levels will be assessed between TMS treatment responders and non-responders using LC-MS/MS. The analysis aims to identify significantly altered metabolites that may predict treatment response.
Time frame: Baseline
Variable Importance in Projection Scores of Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders
Variable Importance in Projection scores will be calculated using multivariate statistical models (e.g., PLS-DA) to rank baseline plasma metabolomic markers according to their importance in differentiating TMS treatment responders from non-responders. Unitless
Time frame: Baseline and End of 4-week treatment
Area Under the ROC Curve of Baseline Plasma Metabolomic Markers Between TMS Responders and Non-Responders
Receiver Operating Characteristic curve analysis will be conducted to evaluate the predictive accuracy of baseline plasma metabolomic markers in distinguishing TMS treatment responders from non-responders. The Area Under Curve (AUC)will quantify each marker's discriminative ability. Measurement Tool: ROC curve analysis Unit of Measure: AUC (0-1 scale)
Time frame: Baseline and End of 4-week treatment
Change in Depression Severity Based on Hamilton Depression Rating Scale (HAM-D, 17-item)
Depression severity will be assessed using the 17-item clinician-administered HAM-D scale. Scores range from 0 to 34, with higher scores indicating more severe depressive symptoms. A clinical response is defined as a ≥50% reduction in HAM-D total score from baseline to post-treatment
Time frame: From enrollment to the end of the treatment at 4 weeks
Change in Depression Severity Based on Patient Health Questionnaire-9 (PHQ-9)
Depression severity will be self-assessed by participants using the PHQ-9 scale. Scores range from 0 to 27, with higher scores reflecting more severe symptoms. A clinical response is defined as a ≥50% reduction in PHQ-9 total score from baseline to post-treatment.
Time frame: From enrollment to the end of the treatment at 4 weeks
Change in Subjective Sleep Quality Measured by Pittsburgh Sleep Quality Index [Sleep Quality]
Subjective sleep quality will be assessed using the Pittsburgh Sleep Quality Index(PSQI) a self-reported questionnaire consisting of 24 items that evaluate sleep quality over the past month across seven domains (e.g., sleep latency, duration, disturbances). Total score range: 0 to 21. Minimum possible score: 0 (indicating good sleep quality). Maximum possible score: 21 (indicating poor sleep quality). Interpretation: Higher scores indicate worse sleep quality. Changes in PSQI total scores from baseline to the end of the 4-week treatment period will be analyzed.
Time frame: From enrollment to end of the treatment 4 weeks
Correlation Between Antidepressant Medication Use and Clinical Response to TMS Measured by Hamilton Depression Rating Scale-17
This outcome will assess the correlation between concurrent antidepressant medication use and clinical response to Transcranial Magnetic Stimulation (TMS). Medication data collected: Drug name, dosage, duration. Clinical outcome: Change in Hamilton Depression Rating Scale-17 (HAM-D17) total score from baseline to end of treatment. Statistical method: Pearson or Spearman correlation (based on data distribution). Unit of Measure (Antidepressant Use): Continuous (daily dose in mg), duration in weeks. Unit of Measure (TMS Response): Change in HAM-D17 total score
Time frame: From enrollment to end of the treatment at 4 weeks
Change in Headache and Scalp Pain Severity Measured by Visual Analog Scale (VAS) [Tolerability]
Change in Headache and Scalp Pain Severity Measured by Visual Analog Scale (VAS) \[Tolerability\]
Time frame: Baseline and End of 4-week treatment
Incidence of Seizure Events
The number and percentage of participants who experience seizures during the 4-week treatment period will be recorded. Events will be classified according to severity and assessed for their relationship to the study intervention.
Time frame: From enrollment to end of the 4 weeks
Plan to share: Yes — Individual Participant Data (IDP) will be shared together with the Clinical Study Report
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: The data will be made available immediately after the publication, and will remain available for at least 5 years.
Access criteria: Anyone who wishes to access the data
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 18 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gulhane Training and Research Hospital